Published: 15, Sep 2026

Pharmacovigilance Market

Pharmacovigilance Market Size, Share and Analysis By Service Provider (In-House, Contract Outsourcing), By Type (Spontaneous Reporting, EHR Mining, Cohort Event Monitoring, Targeted Spontaneous Reporting, Intensified ADR Reporting), By Process Flow (Signal Detection, Case Data Management, Adverse Event Logging, Risk Management, Case Logging), By Product Life Cycle (Phase IV, Phase III, Phase II, Phase I, Pre-Clinical), By Therapeutic Area (Oncology, Neurology, Cardiology, Respiratory Systems, Others), and Regional Forecast Till 2034

Download Free Sample

Market Size (2025):

USD 9.8 Billion

CAGR (2026–2034):

9.3%

Report Pages:

170-180

Market Tables:

55-65

Table of Content

Get a free sample of this report

Overview

The global Pharmacovigilance Market was valued at USD 9.8 billion in 2025 and is projected to reach USD 21.6 billion by 2034, growing at a CAGR of 9.3% during the forecast period (2026-2034). The market growth is driven by increasing adverse drug reaction reporting, stringent drug safety regulations, rising pharmaceutical clinical trials, growing adoption of pharmacovigilance outsourcing. The market is shifting from largely manual, spreadsheet- and email-driven case intake toward AI-enabled, agentic pharmacovigilance platforms capable of automating case triage, narrative writing, literature surveillance, and aggregate regulatory reporting. Government initiatives such as the U.S. FDA's January 2025 draft guidance on the use of artificial intelligence in regulatory decision-making for drugs and biological products, the International Council for Harmonisation's completion of the final ICH E2B(R3) electronic case-safety-report training module in February 2026, and the phased application of high-risk system obligations under the European Union's AI Act from August 2026 are together shaping how AI-supported signal detection and case processing tools must be validated, documented, and deployed across regulated markets. By region, North America held the largest share of the pharmacovigilance market in 2025, supported by a dense concentration of pharmaceutical and biotechnology sponsors, a mature contract-outsourcing ecosystem, and stringent FDA post-marketing surveillance requirements. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by expanding clinical-trial volumes, growing generic and biosimilar manufacturing, and rising government emphasis on drug-safety infrastructure across China, India, and Japan.

Market Size & Share

CAGR (2026–2034):

Market Snapshot

Study Period:	2021-2034
Market Size in 2025:	USD 9.8 Billion
Market Size in 2026:	USD 10.7 Billion
Market Size by 2034:	USD 21.6 Billion
Unit Value:	USD Billion
Projected CAGR:	9.3% (2026-2034)
Largest Region:	North America
Fastest-Growing Region:	Asia-Pacific
Fastest-Growing End User:	Biotechnology Companies

Market Dynamics

KEY MARKET TREND:

Agentic AI and Generative Case-Processing Automation Emerging as a Transformational Trend

Contract research organizations and technology vendors are deploying generative AI and agentic workflow tools to automate high-volume, repetitive case-intake, triage, and narrative-writing tasks that previously consumed the largest share of pharmacovigilance operating budgets.
Vendors including Oracle, Veeva Systems, ArisGlobal, and RxLogix are embedding large-language-model capabilities directly into established safety databases such as Argus and Vault Safety, enabling faster literature surveillance and automated regulatory-report drafting.
Industry alliances such as CIOMS Working Group XIV and joint FDA-EMA principles on the use of AI in pharmacovigilance are shaping validation and documentation expectations for AI-assisted signal detection before wider adoption across regulated markets.
RxLogix Systems Inc., a U.S.-based pharmacovigilance solutions provider, launched an enhanced PVOne.AI platform, reflecting continued vendor investment in agentic automation for case processing and aggregate safety reporting.

KEY MARKET DRIVER:

Rising Global Regulatory Scrutiny and Growing Drug-Pipeline Complexity is the Key Driver

Regulators worldwide are enforcing stricter post-marketing safety-monitoring obligations for biologics, gene therapies, and other complex modalities, requiring sponsors to maintain robust signal-detection and case-management infrastructure throughout the product lifecycle.
The growing volume and complexity of adverse-event data generated by real-world evidence sources, electronic health records, and social-media listening is increasing demand for scalable, AI-assisted case-processing and analytics capability.
Pharmaceutical and biotechnology sponsors are increasingly outsourcing pharmacovigilance operations to specialized contract research organizations to manage cost pressure while maintaining compliance with evolving global reporting timelines.
Government initiatives such as the European Union Good Pharmacovigilance Practices (GVP) framework and the 2025 amendment to EU pharmacovigilance legislation strengthen safety monitoring, signal detection, and reporting requirements for medicinal products, increasing regulatory compliance needs across pharmaceutical companies.

KEY MARKET OPPORTUNITY:

Expansion of AI-Powered Signal Detection Platforms Creates Significant Market Opportunity

Growing adoption of predictive, AI-based signal-detection models is opening new revenue streams for software and platform vendors seeking to help sponsors identify rare and serious adverse events earlier in the product lifecycle.
Emerging biotechnology companies developing cell and gene therapies represent a comparatively underpenetrated customer segment for specialized, flexible pharmacovigilance service models that scale with smaller clinical-trial portfolios.
Consolidation among service providers is creating opportunities for mid-sized and regional specialists to expand through acquisition, adding therapeutic-area depth and platform capability to their existing safety-service portfolios.
Worldwide Clinical Trials agreed to acquire Catalyst Clinical Research, an oncology-focused contract research organization, expanding its oncology-specific pharmacovigilance and clinical safety-monitoring capabilities.

Pharmacovigilance Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Type

Spontaneous reporting held the largest market share in 2025, supported by its established role as the primary passive-surveillance mechanism used by regulators, healthcare professionals, and patients to flag suspected adverse drug reactions after a product reaches the market. Its low implementation cost, broad regulatory acceptance, and long operating history across national pharmacovigilance centers make it the default reporting mechanism embedded in most sponsor and regulator workflows, particularly for widely prescribed, long-established medicines where large-scale, real-world reporting volumes remain the most practical route to detecting rare or delayed safety signals.

EHR mining is projected to grow at the fastest CAGR during the forecast period, driven by increasing access to structured and unstructured electronic health record data and growing sponsor interest in proactively identifying safety signals from real-world clinical documentation rather than relying solely on voluntary reporting. Advances in natural-language processing are improving the accuracy of extracting adverse-event mentions from clinician notes, supporting broader adoption of EHR-mining approaches alongside traditional passive-surveillance methods.

Type categories include

· Spontaneous Reporting (Dominating Segment)

· EHR Mining (Highest CAGR Segment)

· Cohort Event Monitoring

· Targeted Spontaneous Reporting

· Intensified ADR Reporting

Analysis by Process Flow

Signal detection held the largest market in 2025, because of its central function in identifying potential safety risks from large, heterogeneous adverse-event datasets. Growing use of machine-learning-based pattern recognition is improving both the speed and accuracy with which sponsors and regulators can flag unexpected adverse events, reinforcing signal detection's role as the analytical core of modern pharmacovigilance operations across therapeutic areas and product types.

Case data management is projected to grow at the fastest CAGR during the forecast period, supported by the rising volume of individual case safety reports generated across expanding clinical-trial and post-marketing programs. Automation of case intake, data entry, and quality-check workflows through AI-enabled tools is reducing manual processing time, allowing sponsors to manage growing case volumes without proportionally increasing headcount, which is accelerating adoption of dedicated case-data-management platforms and outsourced processing capacity.

Process Flow categories include

· Signal Detection (Dominating Segment)

· Case Data Management (Highest CAGR Segment)

· Adverse Event Logging

· Risk Management

· Case Logging

Analysis by Product Life Cycle

The Phase IV segment held the largest market share in 2025, reflecting the fact that the majority of adverse-event volume and long-term safety monitoring occurs after a product receives marketing authorization and is used across broad, diverse patient populations. Regulatory agencies require sustained post-approval safety surveillance, including periodic benefit-risk evaluation reports, which keeps post-marketing pharmacovigilance activity the dominant demand driver for case-processing and signal-detection services.

Phase III is projected to grow at the fastest CAGR during the forecast period, supported by expanding late-stage clinical-trial activity across oncology, immunology, and rare-disease therapeutic areas, where large multi-country trial populations generate substantial volumes of safety data requiring rigorous adverse-event monitoring ahead of regulatory submission. Growing biotechnology-sponsor investment in pivotal trials for novel biologics and cell and gene therapies is expected to sustain demand for dedicated Phase III pharmacovigilance support.

Product Life Cycle categories include

· Phase IV (Dominating Segment)

· Phase III (Highest CAGR Segment)

· Phase II

· Phase I

· Pre-Clinical

Analysis by Therapeutic Area

Oncology held the largest market share within the therapeutic-area segment in 2025, driven by the rising global prevalence of cancer and the growing complexity of targeted therapies, immunotherapies, and chemotherapy regimens that require rigorous, ongoing safety monitoring. Biopharmaceutical companies' sustained research investment in novel oncology treatments, combined with regulators' emphasis on close post-approval surveillance of high-risk therapies, continues to reinforce oncology's leading position across the pharmacovigilance value chain.

Neurology is projected to grow at the fastest CAGR during the forecast period, supported by an expanding pipeline of therapies for neurodegenerative and rare neurological conditions, many of which involve novel mechanisms of action with limited long-term real-world safety data. Growing regulatory attention to central-nervous-system drug safety, combined with rising diagnosis rates for neurological disorders, is expected to increase demand for dedicated pharmacovigilance support within this therapeutic area.

Therapeutic Area categories include

· Oncology (Dominating Segment)

· Neurology (Highest CAGR Segment)

· Cardiology

· Respiratory Systems

· Others

By Region

Pharmacovigilance Market Regional Analysis

Pharmacovigilance Market Share 2025, (%)

Regional Analysis

North America held the largest market share in 2025, accounting for 36% of global market share, supported by a dense concentration of pharmaceutical and biotechnology sponsors, an established contract-outsourcing ecosystem, and stringent U.S. FDA post-marketing surveillance and adverse-event reporting requirements. The United States represents the largest country market in the region, supported by its large base of drug developers, clinical-trial activity, and mature pharmacovigilance infrastructure. Canada maintains a smaller but growing pharmacovigilance-services market supported by Health Canada's post-market safety-monitoring framework, while Mexico is contributing to regional demand through the expansion of pharmaceutical manufacturing and drug-safety requirements. Continued investment in AI-enabled safety platforms by U.S.-headquartered contract research organizations and technology vendors is expected to reinforce North America's leading position through the forecast period.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, driven by expanding clinical-trial activity, growing generic and biosimilar manufacturing capacity, and increasing government emphasis on drug-safety infrastructure across the region. India is expected to be the fastest-growing country market, supported by its large, cost-competitive pool of pharmacovigilance and clinical-data-management talent and continued growth in outsourced case-processing capacity for global sponsors. China represents the largest country market in Asia-Pacific, supported by its expanding domestic biopharmaceutical sector and evolving National Medical Products Administration safety-reporting requirements. Japan maintains a rigorous post-marketing surveillance framework through the Pharmaceuticals and Medical Devices Agency, while South Korea and the Rest of Asia-Pacific are contributing to regional growth through expanding pharmaceutical activity and strengthening drug-safety systems.

Countries and Regions Covered

North America (Dominating Region)

o United States (Largest Country Market)

o Mexico

o Canada

Asia-Pacific (Fastest-Growing Region)

o India (Fastest-Growing Country Market)

o China (Largest Country Market in APAC)

o Japan

o South Korea

o Rest of Asia-Pacific

Europe

o Germany (Largest Country Market)

o United Kingdom

o France

o Italy

o Rest of Europe

Latin America

o Brazil (Largest Country Market)

o U.A.E

o Rest of Latin America

Middle East & Africa

o Saudi Arabia (Largest Country Market)

o United Arab Emirates (Fastest-Growing Country Market)

o Rest of Middle East & Africa

Market Share

The market is fragmented, with large global contract research organizations and IT-services firms such as IQVIA, Accenture, ICON, Parexel, Cognizant, Wipro, Tata Consultancy Services, Capgemini, IBM, Genpact, Syneos Health, Fortrea, Medpace, Indegene, and Ergomed competing across drug-safety operations, case processing, signal management, regulatory reporting, and end-to-end pharmacovigilance services. The top ten players are estimated to account for roughly a third of total market revenue, reflecting a competitive landscape shaped by stringent regulatory-compliance requirements, high switching costs associated with established safety-database deployments, and the need for deep therapeutic-area and multi-jurisdictional regulatory expertise. Leading companies are prioritizing investment in generative and agentic AI capability, expansion of proprietary and integrated safety solutions, and continued mergers and acquisitions to broaden therapeutic-area coverage and global delivery capacity, while smaller regional specialists are competing on cost efficiency and flexible, scalable service models for emerging biotechnology sponsors.

Key Players

· IQVIA Holdings Inc. (United States)

· Accenture plc (Ireland)

· ICON plc (Ireland)

· Parexel International Corporation (United States)

· Cognizant Technology Solutions Corporation (United States)

· Wipro Limited (India)

· Tata Consultancy Services Limited (India)

· Capgemini SE (France)

· International Business Machines Corporation (United States)

· Genpact Limited (United States)

· Syneos Health, Inc. (United States)

· Fortrea Holdings, Inc. (United States)

· Medpace Holdings, Inc. (United States)

· Indegene Limited (India)

· Ergomed plc (United Kingdom)

Recent Market Developments

August 2025: Selta Square partnered with Oracle to automate pharmacovigilance case processing and global regulatory reporting for the South Korean market, expanding Oracle Argus-based deployment across Asia-Pacific.
September 2025: ACL Digital acquired Symbiance, a contract research organization with pharmacovigilance capabilities, strengthening its drug-safety and regulatory-affairs service portfolio.
January 2026: QPS Holdings selected Oracle Argus to enhance pharmacovigilance operations across its clinical-trial programs, reflecting continued contract-research-organization adoption of integrated safety databases.
September 2026: Veeva Systems launched Falcon Safety, an agentic safety operations product designed to streamline adverse-event intake, case processing, and follow-up for biopharma companies.

Frequently Asked Questions

What is the Pharmacovigilance Market?

The Pharmacovigilance Market covers the science, services, and technology platforms used to detect, assess, understand, and prevent adverse drug reactions and other drug-related safety issues across the product lifecycle, spanning clinical trials through post-marketing surveillance.